Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track CERENO with free AI briefings, catalyst countdowns, and dilution alerts.

CERENO

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

Follow CERENO by email Get an email when CERENO pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about CERENO, unsubscribe in one click. Privacy

🧪 Trial & FDA Catalysts

Feb 2029 · Phase 2 · Upcoming Trial · CS1 Added to Standard of Care Therapy for Pulmonary Arterial Hypertension
Registry primary completion date, not a results date

📊 Drug Pipeline

Drug	Indication	Most advanced trial	Status
SLAM Family Member 7	Pulmonary Arterial Hypertension	Phase 2 · NCT07761572	Not yet recruiting
CS1 Administration	Pulmonary Arterial Hypertension	Phase 2 · NCT05224531	Completed
CS1-Sodium Valproate	Thrombosis	Phase 1 · NCT03903302	Completed

Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it

Get the full CERENO picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for CERENO and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z